nodes	percent_of_prediction	percent_of_DWPC	metapath
Degarelix—GNRHR—Hormone ligand-binding receptors—TSHR—thyroid cancer	0.0469	0.445	CbGpPWpGaD
Degarelix—GNRHR—Peptide GPCRs—TSHR—thyroid cancer	0.00946	0.0898	CbGpPWpGaD
Degarelix—Alopecia—Vandetanib—thyroid cancer	0.00627	0.007	CcSEcCtD
Degarelix—Breast disorder—Sorafenib—thyroid cancer	0.00625	0.00698	CcSEcCtD
Degarelix—Mental disorder—Vandetanib—thyroid cancer	0.00621	0.00694	CcSEcCtD
Degarelix—Malnutrition—Vandetanib—thyroid cancer	0.00617	0.0069	CcSEcCtD
Degarelix—Muscle spasms—Vandetanib—thyroid cancer	0.00593	0.00663	CcSEcCtD
Degarelix—Febrile neutropenia—Epirubicin—thyroid cancer	0.00585	0.00654	CcSEcCtD
Degarelix—Vision blurred—Vandetanib—thyroid cancer	0.00582	0.0065	CcSEcCtD
Degarelix—Transaminases increased—Epirubicin—thyroid cancer	0.00579	0.00647	CcSEcCtD
Degarelix—Pelvic pain—Epirubicin—thyroid cancer	0.00579	0.00647	CcSEcCtD
Degarelix—Abdominal discomfort—Sorafenib—thyroid cancer	0.00573	0.0064	CcSEcCtD
Degarelix—Erectile dysfunction—Sorafenib—thyroid cancer	0.0055	0.00615	CcSEcCtD
Degarelix—Febrile neutropenia—Doxorubicin—thyroid cancer	0.00541	0.00605	CcSEcCtD
Degarelix—Weight decreased—Sorafenib—thyroid cancer	0.00541	0.00604	CcSEcCtD
Degarelix—Transaminases increased—Doxorubicin—thyroid cancer	0.00535	0.00598	CcSEcCtD
Degarelix—Pelvic pain—Doxorubicin—thyroid cancer	0.00535	0.00598	CcSEcCtD
Degarelix—Hypertension—Vandetanib—thyroid cancer	0.00533	0.00596	CcSEcCtD
Degarelix—Arthralgia—Vandetanib—thyroid cancer	0.00525	0.00587	CcSEcCtD
Degarelix—Acute coronary syndrome—Sorafenib—thyroid cancer	0.00525	0.00587	CcSEcCtD
Degarelix—Renal failure—Sorafenib—thyroid cancer	0.00524	0.00585	CcSEcCtD
Degarelix—Myocardial infarction—Sorafenib—thyroid cancer	0.00522	0.00584	CcSEcCtD
Degarelix—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00522	0.00583	CcSEcCtD
Degarelix—Dry mouth—Vandetanib—thyroid cancer	0.00514	0.00574	CcSEcCtD
Degarelix—Hepatobiliary disease—Sorafenib—thyroid cancer	0.00504	0.00563	CcSEcCtD
Degarelix—Nervous system disorder—Vandetanib—thyroid cancer	0.00494	0.00552	CcSEcCtD
Degarelix—GNRHR—GPCR ligand binding—CALCB—thyroid cancer	0.00491	0.0466	CbGpPWpGaD
Degarelix—Skin disorder—Vandetanib—thyroid cancer	0.00489	0.00547	CcSEcCtD
Degarelix—Urinary tract disorder—Sorafenib—thyroid cancer	0.00472	0.00528	CcSEcCtD
Degarelix—Urethral disorder—Sorafenib—thyroid cancer	0.00469	0.00524	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00459	0.00513	CcSEcCtD
Degarelix—Insomnia—Vandetanib—thyroid cancer	0.00456	0.00509	CcSEcCtD
Degarelix—Dyspnoea—Vandetanib—thyroid cancer	0.00449	0.00502	CcSEcCtD
Degarelix—Abscess—Epirubicin—thyroid cancer	0.00445	0.00497	CcSEcCtD
Degarelix—Cardiac disorder—Sorafenib—thyroid cancer	0.00444	0.00496	CcSEcCtD
Degarelix—Decreased appetite—Vandetanib—thyroid cancer	0.00438	0.00489	CcSEcCtD
Degarelix—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00435	0.00486	CcSEcCtD
Degarelix—Fatigue—Vandetanib—thyroid cancer	0.00434	0.00485	CcSEcCtD
Degarelix—Angiopathy—Sorafenib—thyroid cancer	0.00434	0.00485	CcSEcCtD
Degarelix—Immune system disorder—Sorafenib—thyroid cancer	0.00432	0.00483	CcSEcCtD
Degarelix—Mediastinal disorder—Sorafenib—thyroid cancer	0.00431	0.00482	CcSEcCtD
Degarelix—Constipation—Vandetanib—thyroid cancer	0.00431	0.00481	CcSEcCtD
Degarelix—Pain—Vandetanib—thyroid cancer	0.00431	0.00481	CcSEcCtD
Degarelix—Arrhythmia—Sorafenib—thyroid cancer	0.00427	0.00478	CcSEcCtD
Degarelix—Alopecia—Sorafenib—thyroid cancer	0.00423	0.00472	CcSEcCtD
Degarelix—Mental disorder—Sorafenib—thyroid cancer	0.00419	0.00468	CcSEcCtD
Degarelix—Erythema—Sorafenib—thyroid cancer	0.00416	0.00465	CcSEcCtD
Degarelix—Malnutrition—Sorafenib—thyroid cancer	0.00416	0.00465	CcSEcCtD
Degarelix—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00412	0.0046	CcSEcCtD
Degarelix—Abscess—Doxorubicin—thyroid cancer	0.00412	0.0046	CcSEcCtD
Degarelix—Breast pain—Epirubicin—thyroid cancer	0.00403	0.00451	CcSEcCtD
Degarelix—Muscle spasms—Sorafenib—thyroid cancer	0.004	0.00447	CcSEcCtD
Degarelix—Abdominal pain—Vandetanib—thyroid cancer	0.00398	0.00445	CcSEcCtD
Degarelix—Body temperature increased—Vandetanib—thyroid cancer	0.00398	0.00445	CcSEcCtD
Degarelix—Bone disorder—Epirubicin—thyroid cancer	0.0039	0.00436	CcSEcCtD
Degarelix—Anaemia—Sorafenib—thyroid cancer	0.00385	0.0043	CcSEcCtD
Degarelix—Nocturia—Epirubicin—thyroid cancer	0.00379	0.00424	CcSEcCtD
Degarelix—Breast pain—Doxorubicin—thyroid cancer	0.00373	0.00417	CcSEcCtD
Degarelix—Blood bilirubin increased—Epirubicin—thyroid cancer	0.00372	0.00416	CcSEcCtD
Degarelix—Inflammation—Epirubicin—thyroid cancer	0.00363	0.00406	CcSEcCtD
Degarelix—Asthenia—Vandetanib—thyroid cancer	0.00361	0.00404	CcSEcCtD
Degarelix—Bone disorder—Doxorubicin—thyroid cancer	0.00361	0.00403	CcSEcCtD
Degarelix—Hypertension—Sorafenib—thyroid cancer	0.00359	0.00402	CcSEcCtD
Degarelix—Pruritus—Vandetanib—thyroid cancer	0.00356	0.00398	CcSEcCtD
Degarelix—Musculoskeletal pain—Epirubicin—thyroid cancer	0.00356	0.00398	CcSEcCtD
Degarelix—Arthralgia—Sorafenib—thyroid cancer	0.00354	0.00396	CcSEcCtD
Degarelix—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00352	0.00393	CcSEcCtD
Degarelix—Phosphatase alkaline increased—Epirubicin—thyroid cancer	0.00352	0.00393	CcSEcCtD
Degarelix—Nocturia—Doxorubicin—thyroid cancer	0.00351	0.00392	CcSEcCtD
Degarelix—Injection site reaction—Epirubicin—thyroid cancer	0.0035	0.00391	CcSEcCtD
Degarelix—Dry mouth—Sorafenib—thyroid cancer	0.00347	0.00387	CcSEcCtD
Degarelix—Diarrhoea—Vandetanib—thyroid cancer	0.00345	0.00385	CcSEcCtD
Degarelix—Blood bilirubin increased—Doxorubicin—thyroid cancer	0.00344	0.00385	CcSEcCtD
Degarelix—Influenza like illness—Epirubicin—thyroid cancer	0.00342	0.00382	CcSEcCtD
Degarelix—Anaphylactic shock—Sorafenib—thyroid cancer	0.0034	0.0038	CcSEcCtD
Degarelix—Inflammation—Doxorubicin—thyroid cancer	0.00336	0.00375	CcSEcCtD
Degarelix—Nervous system disorder—Sorafenib—thyroid cancer	0.00333	0.00372	CcSEcCtD
Degarelix—Dizziness—Vandetanib—thyroid cancer	0.00333	0.00372	CcSEcCtD
Degarelix—Skin disorder—Sorafenib—thyroid cancer	0.0033	0.00369	CcSEcCtD
Degarelix—Musculoskeletal pain—Doxorubicin—thyroid cancer	0.0033	0.00368	CcSEcCtD
Degarelix—Phosphatase alkaline increased—Doxorubicin—thyroid cancer	0.00326	0.00364	CcSEcCtD
Degarelix—Injection site reaction—Doxorubicin—thyroid cancer	0.00324	0.00362	CcSEcCtD
Degarelix—Vomiting—Vandetanib—thyroid cancer	0.0032	0.00358	CcSEcCtD
Degarelix—Rash—Vandetanib—thyroid cancer	0.00318	0.00355	CcSEcCtD
Degarelix—Dermatitis—Vandetanib—thyroid cancer	0.00317	0.00355	CcSEcCtD
Degarelix—Influenza like illness—Doxorubicin—thyroid cancer	0.00316	0.00354	CcSEcCtD
Degarelix—Headache—Vandetanib—thyroid cancer	0.00316	0.00353	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.0031	0.00346	CcSEcCtD
Degarelix—Mental disability—Epirubicin—thyroid cancer	0.00305	0.00341	CcSEcCtD
Degarelix—Dyspnoea—Sorafenib—thyroid cancer	0.00303	0.00339	CcSEcCtD
Degarelix—Nausea—Vandetanib—thyroid cancer	0.00299	0.00334	CcSEcCtD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.00299	0.0283	CbGpPWpGaD
Degarelix—Decreased appetite—Sorafenib—thyroid cancer	0.00295	0.0033	CcSEcCtD
Degarelix—Diabetes mellitus—Epirubicin—thyroid cancer	0.00294	0.00328	CcSEcCtD
Degarelix—Blood alkaline phosphatase increased—Epirubicin—thyroid cancer	0.00294	0.00328	CcSEcCtD
Degarelix—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00293	0.00328	CcSEcCtD
Degarelix—Fatigue—Sorafenib—thyroid cancer	0.00293	0.00327	CcSEcCtD
Degarelix—Constipation—Sorafenib—thyroid cancer	0.00291	0.00325	CcSEcCtD
Degarelix—Pain—Sorafenib—thyroid cancer	0.00291	0.00325	CcSEcCtD
Degarelix—Mental disability—Doxorubicin—thyroid cancer	0.00283	0.00316	CcSEcCtD
Degarelix—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00278	0.00311	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—CALCB—thyroid cancer	0.00278	0.0263	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—CDK1—thyroid cancer	0.00273	0.0259	CbGpPWpGaD
Degarelix—Hot flush—Epirubicin—thyroid cancer	0.00273	0.00305	CcSEcCtD
Degarelix—Diabetes mellitus—Doxorubicin—thyroid cancer	0.00272	0.00304	CcSEcCtD
Degarelix—Blood alkaline phosphatase increased—Doxorubicin—thyroid cancer	0.00272	0.00304	CcSEcCtD
Degarelix—Menopausal symptoms—Epirubicin—thyroid cancer	0.00271	0.00303	CcSEcCtD
Degarelix—Urticaria—Sorafenib—thyroid cancer	0.0027	0.00302	CcSEcCtD
Degarelix—Abdominal pain—Sorafenib—thyroid cancer	0.00269	0.003	CcSEcCtD
Degarelix—Body temperature increased—Sorafenib—thyroid cancer	0.00269	0.003	CcSEcCtD
Degarelix—Renal impairment—Epirubicin—thyroid cancer	0.00268	0.003	CcSEcCtD
Degarelix—Cardiac failure—Epirubicin—thyroid cancer	0.00262	0.00293	CcSEcCtD
Degarelix—Hot flush—Doxorubicin—thyroid cancer	0.00253	0.00282	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—CALCB—thyroid cancer	0.00252	0.0239	CbGpPWpGaD
Degarelix—Menopausal symptoms—Doxorubicin—thyroid cancer	0.00251	0.0028	CcSEcCtD
Degarelix—Hypersensitivity—Sorafenib—thyroid cancer	0.0025	0.0028	CcSEcCtD
Degarelix—Renal impairment—Doxorubicin—thyroid cancer	0.00248	0.00278	CcSEcCtD
Degarelix—Asthenia—Sorafenib—thyroid cancer	0.00244	0.00273	CcSEcCtD
Degarelix—Cardiac failure—Doxorubicin—thyroid cancer	0.00242	0.00271	CcSEcCtD
Degarelix—Pruritus—Sorafenib—thyroid cancer	0.0024	0.00269	CcSEcCtD
Degarelix—Diarrhoea—Sorafenib—thyroid cancer	0.00232	0.0026	CcSEcCtD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.00232	0.022	CbGpPWpGaD
Degarelix—Breast disorder—Epirubicin—thyroid cancer	0.00231	0.00258	CcSEcCtD
Degarelix—GNRHR—GPCR ligand binding—TSHR—thyroid cancer	0.00227	0.0216	CbGpPWpGaD
Degarelix—Muscular weakness—Epirubicin—thyroid cancer	0.00225	0.00252	CcSEcCtD
Degarelix—Dizziness—Sorafenib—thyroid cancer	0.00225	0.00251	CcSEcCtD
Degarelix—Vomiting—Sorafenib—thyroid cancer	0.00216	0.00241	CcSEcCtD
Degarelix—Rash—Sorafenib—thyroid cancer	0.00214	0.00239	CcSEcCtD
Degarelix—Dermatitis—Sorafenib—thyroid cancer	0.00214	0.00239	CcSEcCtD
Degarelix—Breast disorder—Doxorubicin—thyroid cancer	0.00214	0.00239	CcSEcCtD
Degarelix—Headache—Sorafenib—thyroid cancer	0.00213	0.00238	CcSEcCtD
Degarelix—Muscular weakness—Doxorubicin—thyroid cancer	0.00209	0.00233	CcSEcCtD
Degarelix—Dysuria—Epirubicin—thyroid cancer	0.00206	0.00231	CcSEcCtD
Degarelix—Pollakiuria—Epirubicin—thyroid cancer	0.00204	0.00228	CcSEcCtD
Degarelix—Nausea—Sorafenib—thyroid cancer	0.00202	0.00226	CcSEcCtD
Degarelix—Weight increased—Epirubicin—thyroid cancer	0.00201	0.00225	CcSEcCtD
Degarelix—Weight decreased—Epirubicin—thyroid cancer	0.002	0.00223	CcSEcCtD
Degarelix—Hyperglycaemia—Epirubicin—thyroid cancer	0.00199	0.00223	CcSEcCtD
Degarelix—Renal failure—Epirubicin—thyroid cancer	0.00194	0.00216	CcSEcCtD
Degarelix—GNRHR—GPCR ligand binding—PTCH1—thyroid cancer	0.00193	0.0183	CbGpPWpGaD
Degarelix—Urinary tract infection—Epirubicin—thyroid cancer	0.00191	0.00214	CcSEcCtD
Degarelix—Dysuria—Doxorubicin—thyroid cancer	0.00191	0.00214	CcSEcCtD
Degarelix—Pollakiuria—Doxorubicin—thyroid cancer	0.00189	0.00211	CcSEcCtD
Degarelix—Hepatobiliary disease—Epirubicin—thyroid cancer	0.00186	0.00208	CcSEcCtD
Degarelix—Weight increased—Doxorubicin—thyroid cancer	0.00186	0.00208	CcSEcCtD
Degarelix—Weight decreased—Doxorubicin—thyroid cancer	0.00185	0.00207	CcSEcCtD
Degarelix—Hyperglycaemia—Doxorubicin—thyroid cancer	0.00184	0.00206	CcSEcCtD
Degarelix—Renal failure—Doxorubicin—thyroid cancer	0.00179	0.002	CcSEcCtD
Degarelix—Urinary tract infection—Doxorubicin—thyroid cancer	0.00177	0.00198	CcSEcCtD
Degarelix—GNRHR—GPCR ligand binding—SST—thyroid cancer	0.00177	0.0168	CbGpPWpGaD
Degarelix—Hypoaesthesia—Epirubicin—thyroid cancer	0.00176	0.00197	CcSEcCtD
Degarelix—Urinary tract disorder—Epirubicin—thyroid cancer	0.00175	0.00195	CcSEcCtD
Degarelix—Oedema peripheral—Epirubicin—thyroid cancer	0.00174	0.00195	CcSEcCtD
Degarelix—Urethral disorder—Epirubicin—thyroid cancer	0.00173	0.00194	CcSEcCtD
Degarelix—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.00172	0.00193	CcSEcCtD
Degarelix—GNRHR—GPCR ligand binding—CALCA—thyroid cancer	0.0017	0.0161	CbGpPWpGaD
Degarelix—Eye disorder—Epirubicin—thyroid cancer	0.00165	0.00185	CcSEcCtD
Degarelix—Cardiac disorder—Epirubicin—thyroid cancer	0.00164	0.00183	CcSEcCtD
Degarelix—Hypoaesthesia—Doxorubicin—thyroid cancer	0.00163	0.00182	CcSEcCtD
Degarelix—Urinary tract disorder—Doxorubicin—thyroid cancer	0.00162	0.00181	CcSEcCtD
Degarelix—Oedema peripheral—Doxorubicin—thyroid cancer	0.00161	0.0018	CcSEcCtD
Degarelix—Angiopathy—Epirubicin—thyroid cancer	0.0016	0.00179	CcSEcCtD
Degarelix—Urethral disorder—Doxorubicin—thyroid cancer	0.0016	0.00179	CcSEcCtD
Degarelix—Immune system disorder—Epirubicin—thyroid cancer	0.0016	0.00178	CcSEcCtD
Degarelix—Mediastinal disorder—Epirubicin—thyroid cancer	0.00159	0.00178	CcSEcCtD
Degarelix—Chills—Epirubicin—thyroid cancer	0.00159	0.00177	CcSEcCtD
Degarelix—Arrhythmia—Epirubicin—thyroid cancer	0.00158	0.00177	CcSEcCtD
Degarelix—Alopecia—Epirubicin—thyroid cancer	0.00156	0.00175	CcSEcCtD
Degarelix—Mental disorder—Epirubicin—thyroid cancer	0.00155	0.00173	CcSEcCtD
Degarelix—Erythema—Epirubicin—thyroid cancer	0.00154	0.00172	CcSEcCtD
Degarelix—Malnutrition—Epirubicin—thyroid cancer	0.00154	0.00172	CcSEcCtD
Degarelix—Eye disorder—Doxorubicin—thyroid cancer	0.00153	0.00171	CcSEcCtD
Degarelix—Cardiac disorder—Doxorubicin—thyroid cancer	0.00152	0.0017	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—CALCB—thyroid cancer	0.00149	0.0141	CbGpPWpGaD
Degarelix—Back pain—Epirubicin—thyroid cancer	0.00149	0.00166	CcSEcCtD
Degarelix—Angiopathy—Doxorubicin—thyroid cancer	0.00148	0.00166	CcSEcCtD
Degarelix—Muscle spasms—Epirubicin—thyroid cancer	0.00148	0.00165	CcSEcCtD
Degarelix—Immune system disorder—Doxorubicin—thyroid cancer	0.00148	0.00165	CcSEcCtD
Degarelix—Mediastinal disorder—Doxorubicin—thyroid cancer	0.00147	0.00165	CcSEcCtD
Degarelix—Chills—Doxorubicin—thyroid cancer	0.00147	0.00164	CcSEcCtD
Degarelix—Arrhythmia—Doxorubicin—thyroid cancer	0.00146	0.00163	CcSEcCtD
Degarelix—Vision blurred—Epirubicin—thyroid cancer	0.00145	0.00162	CcSEcCtD
Degarelix—Alopecia—Doxorubicin—thyroid cancer	0.00145	0.00162	CcSEcCtD
Degarelix—Mental disorder—Doxorubicin—thyroid cancer	0.00143	0.0016	CcSEcCtD
Degarelix—Ill-defined disorder—Epirubicin—thyroid cancer	0.00143	0.0016	CcSEcCtD
Degarelix—Malnutrition—Doxorubicin—thyroid cancer	0.00142	0.00159	CcSEcCtD
Degarelix—Erythema—Doxorubicin—thyroid cancer	0.00142	0.00159	CcSEcCtD
Degarelix—Anaemia—Epirubicin—thyroid cancer	0.00142	0.00159	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—TRIM33—thyroid cancer	0.00141	0.0134	CbGpPWpGaD
Degarelix—Malaise—Epirubicin—thyroid cancer	0.00139	0.00155	CcSEcCtD
Degarelix—Back pain—Doxorubicin—thyroid cancer	0.00138	0.00154	CcSEcCtD
Degarelix—Muscle spasms—Doxorubicin—thyroid cancer	0.00137	0.00153	CcSEcCtD
Degarelix—Palpitations—Epirubicin—thyroid cancer	0.00136	0.00152	CcSEcCtD
Degarelix—Vision blurred—Doxorubicin—thyroid cancer	0.00134	0.0015	CcSEcCtD
Degarelix—Hypertension—Epirubicin—thyroid cancer	0.00133	0.00148	CcSEcCtD
Degarelix—Ill-defined disorder—Doxorubicin—thyroid cancer	0.00132	0.00148	CcSEcCtD
Degarelix—Anaemia—Doxorubicin—thyroid cancer	0.00132	0.00147	CcSEcCtD
Degarelix—Arthralgia—Epirubicin—thyroid cancer	0.00131	0.00146	CcSEcCtD
Degarelix—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.0013	0.00145	CcSEcCtD
Degarelix—Discomfort—Epirubicin—thyroid cancer	0.00129	0.00145	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—TSHR—thyroid cancer	0.00128	0.0122	CbGpPWpGaD
Degarelix—Malaise—Doxorubicin—thyroid cancer	0.00128	0.00144	CcSEcCtD
Degarelix—Dry mouth—Epirubicin—thyroid cancer	0.00128	0.00143	CcSEcCtD
Degarelix—Palpitations—Doxorubicin—thyroid cancer	0.00126	0.00141	CcSEcCtD
Degarelix—Anaphylactic shock—Epirubicin—thyroid cancer	0.00126	0.0014	CcSEcCtD
Degarelix—Nervous system disorder—Epirubicin—thyroid cancer	0.00123	0.00138	CcSEcCtD
Degarelix—Hypertension—Doxorubicin—thyroid cancer	0.00123	0.00137	CcSEcCtD
Degarelix—Skin disorder—Epirubicin—thyroid cancer	0.00122	0.00136	CcSEcCtD
Degarelix—Hyperhidrosis—Epirubicin—thyroid cancer	0.00121	0.00136	CcSEcCtD
Degarelix—Arthralgia—Doxorubicin—thyroid cancer	0.00121	0.00135	CcSEcCtD
Degarelix—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.0012	0.00135	CcSEcCtD
Degarelix—Discomfort—Doxorubicin—thyroid cancer	0.0012	0.00134	CcSEcCtD
Degarelix—Dry mouth—Doxorubicin—thyroid cancer	0.00119	0.00133	CcSEcCtD
Degarelix—Hypotension—Epirubicin—thyroid cancer	0.00117	0.00131	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—TSHR—thyroid cancer	0.00117	0.0111	CbGpPWpGaD
Degarelix—Anaphylactic shock—Doxorubicin—thyroid cancer	0.00116	0.0013	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—PRKAR1A—thyroid cancer	0.00115	0.0109	CbGpPWpGaD
Degarelix—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.00114	0.00128	CcSEcCtD
Degarelix—Nervous system disorder—Doxorubicin—thyroid cancer	0.00114	0.00127	CcSEcCtD
Degarelix—Insomnia—Epirubicin—thyroid cancer	0.00114	0.00127	CcSEcCtD
Degarelix—Skin disorder—Doxorubicin—thyroid cancer	0.00113	0.00126	CcSEcCtD
Degarelix—Hyperhidrosis—Doxorubicin—thyroid cancer	0.00112	0.00126	CcSEcCtD
Degarelix—Dyspnoea—Epirubicin—thyroid cancer	0.00112	0.00125	CcSEcCtD
Degarelix—Decreased appetite—Epirubicin—thyroid cancer	0.00109	0.00122	CcSEcCtD
Degarelix—Hypotension—Doxorubicin—thyroid cancer	0.00109	0.00121	CcSEcCtD
Degarelix—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.00108	0.00121	CcSEcCtD
Degarelix—Fatigue—Epirubicin—thyroid cancer	0.00108	0.00121	CcSEcCtD
Degarelix—Constipation—Epirubicin—thyroid cancer	0.00107	0.0012	CcSEcCtD
Degarelix—Pain—Epirubicin—thyroid cancer	0.00107	0.0012	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.00106	0.00118	CcSEcCtD
Degarelix—Insomnia—Doxorubicin—thyroid cancer	0.00105	0.00117	CcSEcCtD
Degarelix—Dyspnoea—Doxorubicin—thyroid cancer	0.00104	0.00116	CcSEcCtD
Degarelix—Feeling abnormal—Epirubicin—thyroid cancer	0.00103	0.00116	CcSEcCtD
Degarelix—Gastrointestinal pain—Epirubicin—thyroid cancer	0.00103	0.00115	CcSEcCtD
Degarelix—Decreased appetite—Doxorubicin—thyroid cancer	0.00101	0.00113	CcSEcCtD
Degarelix—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.001	0.00112	CcSEcCtD
Degarelix—Fatigue—Doxorubicin—thyroid cancer	0.001	0.00112	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—SST—thyroid cancer	0.000999	0.00948	CbGpPWpGaD
Degarelix—Urticaria—Epirubicin—thyroid cancer	0.000998	0.00112	CcSEcCtD
Degarelix—Constipation—Doxorubicin—thyroid cancer	0.000994	0.00111	CcSEcCtD
Degarelix—Pain—Doxorubicin—thyroid cancer	0.000994	0.00111	CcSEcCtD
Degarelix—Body temperature increased—Epirubicin—thyroid cancer	0.000993	0.00111	CcSEcCtD
Degarelix—Abdominal pain—Epirubicin—thyroid cancer	0.000993	0.00111	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—PTCH1—thyroid cancer	0.000992	0.00941	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	0.00098	0.0093	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—CALCA—thyroid cancer	0.000962	0.00913	CbGpPWpGaD
Degarelix—Feeling abnormal—Doxorubicin—thyroid cancer	0.000957	0.00107	CcSEcCtD
Degarelix—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.00095	0.00106	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—TCF7L1—thyroid cancer	0.000942	0.00893	CbGpPWpGaD
Degarelix—Hypersensitivity—Epirubicin—thyroid cancer	0.000925	0.00103	CcSEcCtD
Degarelix—Urticaria—Doxorubicin—thyroid cancer	0.000923	0.00103	CcSEcCtD
Degarelix—Abdominal pain—Doxorubicin—thyroid cancer	0.000919	0.00103	CcSEcCtD
Degarelix—Body temperature increased—Doxorubicin—thyroid cancer	0.000919	0.00103	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—SST—thyroid cancer	0.000907	0.00861	CbGpPWpGaD
Degarelix—Asthenia—Epirubicin—thyroid cancer	0.000901	0.00101	CcSEcCtD
Degarelix—Pruritus—Epirubicin—thyroid cancer	0.000888	0.000993	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—CALCA—thyroid cancer	0.000873	0.00829	CbGpPWpGaD
Degarelix—Diarrhoea—Epirubicin—thyroid cancer	0.000859	0.00096	CcSEcCtD
Degarelix—Hypersensitivity—Doxorubicin—thyroid cancer	0.000856	0.000957	CcSEcCtD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	0.000844	0.008	CbGpPWpGaD
Degarelix—Asthenia—Doxorubicin—thyroid cancer	0.000834	0.000932	CcSEcCtD
Degarelix—Dizziness—Epirubicin—thyroid cancer	0.00083	0.000928	CcSEcCtD
Degarelix—Pruritus—Doxorubicin—thyroid cancer	0.000822	0.000919	CcSEcCtD
Degarelix—Vomiting—Epirubicin—thyroid cancer	0.000798	0.000892	CcSEcCtD
Degarelix—Diarrhoea—Doxorubicin—thyroid cancer	0.000795	0.000889	CcSEcCtD
Degarelix—Rash—Epirubicin—thyroid cancer	0.000792	0.000885	CcSEcCtD
Degarelix—Dermatitis—Epirubicin—thyroid cancer	0.000791	0.000884	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—CDK1—thyroid cancer	0.000791	0.0075	CbGpPWpGaD
Degarelix—Headache—Epirubicin—thyroid cancer	0.000787	0.000879	CcSEcCtD
Degarelix—Dizziness—Doxorubicin—thyroid cancer	0.000768	0.000859	CcSEcCtD
Degarelix—Nausea—Epirubicin—thyroid cancer	0.000746	0.000834	CcSEcCtD
Degarelix—Vomiting—Doxorubicin—thyroid cancer	0.000739	0.000826	CcSEcCtD
Degarelix—Rash—Doxorubicin—thyroid cancer	0.000733	0.000819	CcSEcCtD
Degarelix—Dermatitis—Doxorubicin—thyroid cancer	0.000732	0.000818	CcSEcCtD
Degarelix—Headache—Doxorubicin—thyroid cancer	0.000728	0.000814	CcSEcCtD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	0.000717	0.0068	CbGpPWpGaD
Degarelix—Nausea—Doxorubicin—thyroid cancer	0.00069	0.000771	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—TSHR—thyroid cancer	0.000689	0.00654	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PRKAR1A—thyroid cancer	0.000678	0.00643	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MEN1—thyroid cancer	0.000648	0.00615	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PTCH1—thyroid cancer	0.000586	0.00556	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—SST—thyroid cancer	0.000536	0.00509	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CALCA—thyroid cancer	0.000516	0.0049	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CDK1—thyroid cancer	0.000467	0.00443	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—NRG1—thyroid cancer	0.000375	0.00356	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—TERT—thyroid cancer	0.000337	0.00319	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—HIF1A—thyroid cancer	0.000322	0.00305	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—NRAS—thyroid cancer	0.000284	0.00269	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—BRAF—thyroid cancer	0.000267	0.00253	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—KRAS—thyroid cancer	0.000244	0.00232	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—HRAS—thyroid cancer	0.000207	0.00197	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—AKT1—thyroid cancer	0.000202	0.00191	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CCND1—thyroid cancer	0.000195	0.00185	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PTEN—thyroid cancer	0.000188	0.00178	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—AKT1—thyroid cancer	0.000183	0.00174	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—NRAS—thyroid cancer	0.000168	0.00159	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—KRAS—thyroid cancer	0.000144	0.00137	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—TP53—thyroid cancer	0.000128	0.00122	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—HRAS—thyroid cancer	0.000123	0.00116	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—AKT1—thyroid cancer	0.000108	0.00103	CbGpPWpGaD
